CO-VANTAGE-DATA-CENTERS
24.4.2024 12:01:33 CEST | Business Wire | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced its entrance into the Irish market with the development of a multi-phase data center campus (DUB1). The company will invest more than €1 billion over multiple phases to support the construction and delivery of the campus in one of the largest data center markets in Europe. The first two phases consist of 52MW of IT capacity, with the first phase expected to be operational in late 2024. Upon completion, DUB1 will mark Vantage’s 14th EMEA campus in a growing regional portfolio that spans seven countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424930079/en/
Vantage Data Centers’ flagship Dublin campus will include 52MW of IT capacity to enable next-generation applications and digital transformation. (Graphic: Business Wire)
The company’s flagship Ireland campus will be located approximately nine miles (15 kilometers) from the Dublin City Center in Profile Park, Grange Castle, an area known for its data centers. Sited on 22 acres (nine hectares), the 405,000 square foot (38,000 square meter) campus will consist of one 32MW facility and one 20MW facility and has available land and power to add a third facility in the future. The highly efficient campus is being built in alignment with Vantage’s sustainable blueprint to deliver an industry-leading annualized Power Usage Effectiveness (PUE) of 1.2 using virtually no water for cooling.
Vantage Data Centers is committed to achieving net zero carbon emissions by 2030 and drives emission reductions through the use of renewable energy and sustainable fuel alternatives across its value chain. This aligns with Ireland’s climate action plans and with the environmental commitments of the company’s key customers.
The DUB1 campus will include an on-site 100MVA multi-fuel generation plant capable of running a combination of fuels, primarily hydrotreated vegetable oil (HVO), a renewable fuel, and gas fed by Gas Networks Ireland. Given the temporary power constraints in Dublin, this on-site generation plant will support current capacity constraints by alleviating pressure on energy demand from the grid while achieving optimal efficiency and power output. The generation plant is also capable of funneling power back to the grid, further supporting power availability in the Dublin area. In addition, Vantage plans to deploy HVO in place of conventional diesel fuel throughout its fleet of back-up generators and is working to obtain corporate power purchase agreements (CPPAs) for green energy, such as biomethane from local providers. Currently, the company is leveraging HVO for 99% of its fuel requirements during the construction phase.
“The South Dublin Chamber warmly welcomes the confidence shown in our area through the €1 billion investment by Vantage Data Centers,” said Peter Byrne, CEO, South Dublin Chamber. “Vantage Data Centers will not only be contributing to local employment and taxation but will be ensuring the safety of our data and future-proofing business for years to come with this major investment in technology.”
“With Dublin being one of the biggest data center markets in the world, this expansion further solidifies Vantage’s role at the forefront of the digital infrastructure revolution and signifies the start of a strong partnership with local officials and the community,” said David Howson, president, EMEA at Vantage Data Centers. “Throughout this development, there will be a significant positive economic impact to the community as we employ more than 1,100 individuals during peak construction and create approximately 165 jobs to operate the campus. Vantage is committed to being a good neighbor where we build and operate data centers, and we are eager to continue working with community organizations such as Round Tower GAA Club, Newcastle Tidy Towns, St. Francis Football Club, Ballyboden St. Enda’s GAA, St. Ronan’s National School in Deansrath and others.”
“Vantage is committed to environmental responsibility and is pleased that our sustainability goals, including reducing emissions, achieving net zero carbon emissions by 2030 and maximizing energy efficiency, align closely with those of the Irish government and regulatory bodies as we continue growing Ireland’s position as a leader in the digital age for cloud computing,” said Jinél Fourie, director of public policy, EMEA at Vantage Data Centers. “As environmental technology continues to advance, including the inaugural use of a multi-fuel generation plant in Dublin, we look forward to continuing our local partnerships to explore additional solutions to enhance the local community.”
For more information on Vantage Data Centers’ campuses, please visit: https://vantage-dc.com/data-center-locations/.
About Vantage Data Centers
Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.
For more information, visit www.vantage-dc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424930079/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
